TY - JOUR
T1 - Outcomes of Glaucoma Drainage Device Implantation and Trabeculectomy With Mitomycin C in Glaucoma Secondary to Aniridia
AU - Durai, Indira
AU - Pallamparthy, Srilekha
AU - Puthuran, George Varghese
AU - Wijesinghe, Hiruni Kaushalya
AU - Uduman, Mohammed Sithiq
AU - Krishnadas, Subbaiah Ramasamy
AU - Robin, Alan Lee
AU - Palmberg, Paul
AU - Gedde, Steven J.
N1 - Funding Information:
Funding/Support: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Financial Disclosures: Alan Lee Robin: Executive Vice President, American Glaucoma Society, Consultant: Versant Health, Consultant: Perfuse Therapeutics. Paul Palmberg: Consultant and Medical Monitor for InnFocus, Inc, a Santen company, for the FDA trial of the MicroShunt. This includes honoraria and travel support for attending international meetings to present data from the US-Europe FDA trial of the MicroShunt; in the past year received honoraria and travel support for being an invited speaker at the Moroccan Ophthalmology Society, and UCLA-Doheny, all unrelated to the submitted article. The following authors have no financial disclosures: Indira Durai, Srilekha Pallamparthy, George Varghese Puthuran, Hiruni Kaushalya Wijesinghe, Mohammed Sithiq Uduman, Subbaiah Ramasamy Krishnadas, and Steven J. Gedde. All authors attest that they meet the current ICMJE criteria for authorship.
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/7
Y1 - 2021/7
N2 - Purpose: To compare the outcomes of Aurolab aqueous drainage implant (AADI; Aurolab) placement and trabeculectomy with mitomycin C (MMC) in patients with glaucoma secondary to aniridia. Design: Retrospective comparative interventional case series. Methods: This study included patients with congenital aniridia who underwent AADI implantation or trabeculectomy with MMC. Surgical failure was defined as IOP > 21 mm Hg or reduced <20% from baseline, IOP ≤ 5 mm Hg, reoperation for glaucoma or a complication, or loss of light perception vision. Results: A total of 30 eyes of 30 patients underwent surgical treatment, including 18 eyes that received an AADI and 12 eyes that had a trabeculectomy with MMC. The cumulative probability of failure at 2 years was 11.1% (95% CI = 2.9%-37.6%) in the AADI group and 58.3% (95% CI = 33.5%-84.8%) in the trabeculectomy group (P = .05, log-rank). At 2 years, IOP (mean ± SD) was 14.1 ± 2.8 mm Hg in the AADI group and 19.6 ± 6.6 mm Hg in the trabeculectomy group (P = .02), and the number of glaucoma medications was 1.7 ± 0.9 in the AADI group and 2.2 ± 0.8 in the trabeculectomy group (P = .25). Surgical complications developed in 1 patient in each treatment group (P = .65). Cataract surgery was performed in 5 (42%) patients in the trabeculectomy group and no patients in the AADI group (P = .01). Conclusions: Placement of an AADI resulted in lower IOP and a higher rate of surgical success compared to trabeculectomy with MMC in eyes with glaucoma associated with aniridia. Cataract extraction was more frequently required after trabeculectomy with MMC than AADI implantation.
AB - Purpose: To compare the outcomes of Aurolab aqueous drainage implant (AADI; Aurolab) placement and trabeculectomy with mitomycin C (MMC) in patients with glaucoma secondary to aniridia. Design: Retrospective comparative interventional case series. Methods: This study included patients with congenital aniridia who underwent AADI implantation or trabeculectomy with MMC. Surgical failure was defined as IOP > 21 mm Hg or reduced <20% from baseline, IOP ≤ 5 mm Hg, reoperation for glaucoma or a complication, or loss of light perception vision. Results: A total of 30 eyes of 30 patients underwent surgical treatment, including 18 eyes that received an AADI and 12 eyes that had a trabeculectomy with MMC. The cumulative probability of failure at 2 years was 11.1% (95% CI = 2.9%-37.6%) in the AADI group and 58.3% (95% CI = 33.5%-84.8%) in the trabeculectomy group (P = .05, log-rank). At 2 years, IOP (mean ± SD) was 14.1 ± 2.8 mm Hg in the AADI group and 19.6 ± 6.6 mm Hg in the trabeculectomy group (P = .02), and the number of glaucoma medications was 1.7 ± 0.9 in the AADI group and 2.2 ± 0.8 in the trabeculectomy group (P = .25). Surgical complications developed in 1 patient in each treatment group (P = .65). Cataract surgery was performed in 5 (42%) patients in the trabeculectomy group and no patients in the AADI group (P = .01). Conclusions: Placement of an AADI resulted in lower IOP and a higher rate of surgical success compared to trabeculectomy with MMC in eyes with glaucoma associated with aniridia. Cataract extraction was more frequently required after trabeculectomy with MMC than AADI implantation.
UR - http://www.scopus.com/inward/record.url?scp=85105088681&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105088681&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2021.03.008
DO - 10.1016/j.ajo.2021.03.008
M3 - Article
C2 - 33737035
AN - SCOPUS:85105088681
SN - 0002-9394
VL - 227
SP - 173
EP - 181
JO - American journal of ophthalmology
JF - American journal of ophthalmology
ER -